Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mint Med vs NP2GO

Mint Med
Graded #15Editorial

Higher grade

vs+4
NP2GO
Graded #23Editorial

Lower grade

The verdict

Mint Med takes it — 84/100 to 80/100.

Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states.

Both are editorial reviews with no commercial relationship.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMint Med +9
90
81
Dose & formulationEven
80
80
Clinical oversightMint Med +6
85
79
Labs & monitoringMint Med +5
83
78
FulfillmentEven
82
82
Contract termsMint Med +4
86
82
Mint Med · left barNP2GO · right bar

The numbers

MetricMint MedNP2GO
WeighScore84/10080/100
GradeBB−
Scorecard rank#15#23
Semaglutide$117/mo$150/mo
Tirzepatide$159/mo$250/mo
Coverage36 states40 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
RelationshipEditorialEditorial
Mint Med

Graded #15 · B

Strengths

  • $117 sema / $159 tirz
  • LegitScript-verified
  • Both molecules

Where it loses points

  • Only 36 states
  • Injection-only
  • Monitoring detail sparse
NP2GO

Graded #23 · B−

Strengths

  • Both molecules
  • 40-state footprint
  • Transparent listed pricing

Where it loses points

  • Not LegitScript-verified
  • Upper-mid pricing ($150/$250)
  • Not all 50 states

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard